Scarica l'app Stockscreener
12.35
3.29%
-0.42
Dopo l'orario di chiusura:
12.50
0.15
+1.21%
Precedente Chiudi:
$12.77
Aprire:
$12.75
Volume 24 ore:
945.34K
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.28B
Reddito:
Utile/perdita netta:
$-135.21M
Rapporto P/E:
-8.6297
EPS:
-1.4311
Flusso di cassa netto:
$-114.35M
1 W Prestazione:
+3.00%
1M Prestazione:
-1.52%
6M Prestazione:
+20.72%
1 anno Prestazione:
-7.14%
Intervallo 1D:
$12.03
$12.75
Intervallo di 1 settimana:
$11.20
$12.89
Portata 52W:
$7.23
$14.68
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
12.35 | 1.28B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-05 | Iniziato | Leerink Partners | Outperform |
| 2026-09-23 | Iniziato | BTIG Research | Buy |
| 2026-06-12 | Ripresa | Stifel | Buy |
| 2026-05-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-11-20 | Iniziato | Evercore ISI | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Oric Pharmaceuticals director Heyman sells $86,524 in ORIC stock By Investing.com - Investing.com South Africa
Form 4 Oric Pharmaceuticals Inc: Richard A. Heyman (Director) For: 1 October - Investing.com UK
Cancer Research UK will fund early testing of a potential cancer treatment. - stocktitan.net
A director exercised options at $1.60 and sold 3,500 Oric Pharmaceuticals (ORIC) shares. - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new hires received options to buy shares and stock awards from ORIC Pharmaceuticals - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
A director proposes selling 8,100 shares of Oric Pharmaceuticals (ORIC). - Stock Titan
A proposed sale covers 7,600 Oric Pharmaceuticals (ORIC) shares held by RAHD Capital. - Stock Titan
Oric Pharma CFO sells $181k in shares By Investing.com - Investing.com South Africa
Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com Nigeria
Oric Pharma CFO sells $181k in shares - Investing.com
Form 4 Oric Pharmaceuticals Inc For: 29 September - Investing.com India
Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com - Investing.com UK
After a $4.36 option exercise, Oric Pharmaceuticals (ORIC) CFO sells 13,400 shares. - stocktitan.net
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18 - MarketBeat
1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE - MarketBeat
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares - Investing.com
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares By Investing.com - Investing.com Canada
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com Canada
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com India
A finance chief exercised 600 options and sold 600 shares at Oric Pharmaceuticals (ORIC). - stocktitan.net
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com - Investing.com UK
ORIC Pharmaceuticals (Nasdaq:ORIC)Stock Analysis - Simply Wall Street
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.com.au
Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC - marketbeat.com
Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones - Stock Traders Daily
ORIC: Advancing late-stage prostate and lung cancer programs with robust funding and global trials - TradingView
ORIC: Phase III trials and robust funding position support late-stage oncology pipeline growth - TradingView
ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com Canada
ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com India
Oric Pharmaceuticals joins 2026 Cantor Global Healthcare Conference fireside chat: Can ORIC break above $12.51? - Traders Union
ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView
ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
ORIC stock holds firm as biotech valuation nears 0.93 billion USD - ad-hoc-news.de
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.ca
Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - ad-hoc-news.de
Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan
Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing - Yahoo Finance
ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month HighHere's Why - MarketBeat
Oric (ORIC) Earnings Report: EPS Misses Its Estimate in Latest Trading; After Earnings: The Stock Gains 4.04% in the Latest SessionForward EPS Estimate - vinanet.vn
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Oric Pharmaceuticals Inc Azioni (ORIC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Richard A, Heyman | Director |
Oct 01 '26 |
Proposed Sale |
13.47 |
8,100 |
109,107 |
0 |
| Richard A, Heyman | Director |
Oct 01 '26 |
Proposed Sale |
13.47 |
7,600 |
102,372 |
0 |
| Heyman Richard A. | Director |
Oct 01 '26 |
Sale |
12.91 |
3,500 |
45,199 |
38,300 |
| Heyman Richard A. | Director |
Oct 01 '26 |
Sale |
12.91 |
3,200 |
41,325 |
203,472 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 28 '26 |
Sale |
13.53 |
13,400 |
181,258 |
69,828 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 28 '26 |
Option Exercise |
4.36 |
13,400 |
58,424 |
83,228 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 24 '26 |
Sale |
13.50 |
600 |
8,102 |
69,828 |
| Piscitelli Dominic | Chief Financial Officer |
Sep 24 '26 |
Option Exercise |
4.36 |
600 |
2,616 |
70,428 |
| Dominic Piscitelli | Officer |
Aug 26 '26 |
Proposed Sale |
13.50 |
229,500 |
3,098,250 |
0 |
| Piscitelli Dominic | Chief Financial Officer |
Aug 26 '26 |
Sale |
13.69 |
77,000 |
1,053,814 |
69,828 |
2.73%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):